Who is sponsoring NCT05202119?

NCT05202119 is sponsored by Flow Neuroscience AB.

What drugs are being tested in NCT05202119?

Interventions in NCT05202119: Transcranial direct current stimulation, Sham Transcranial direct current stimulation.

What condition does NCT05202119 study?

NCT05202119 studies Major Depressive Disorder.

Is NCT05202119 still recruiting?

NCT05202119 is currently completed. Last updated 19 September 2024.

Last reviewed 2024-09-19 · How we verify

NCT05202119

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Empower: tDCS for Major Depressive Disorder at Home

Completed NA Last updated 19 September 2024

What this trial tests

NA trial testing Transcranial direct current stimulation in Major Depressive Disorder in 174 participants. Completed in 31 August 2023.

Timeline

1 May 2022

Primary endpoint
6 June 2023

31 August 2023

Quick facts

Lead sponsor	Flow Neuroscience AB
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	174
Start date	1 May 2022
Primary completion	6 June 2023
Estimated completion	31 August 2023
Sites	2 locations across United Kingdom, United States

Drugs / interventions tested

Transcranial direct current stimulation
Sham Transcranial direct current stimulation

Conditions studied

Major Depressive Disorder — all drugs for Major Depressive Disorder →

Sponsor

Flow Neuroscience AB

Who can join

18 and older, any sex, with Major Depressive Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A two-center trial to investigate whether or not active stimulation with the Flow FL-100 tDCS device is superior to sham stimulation for the treatment of major depressive disorder when used at home. Participants perform up to 36 tDCS sessions by themselves without supervision during a blinded 10-week phase, and then 30 more sessions during an unblinded open-label phase.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Home-based transcranial direct current stimulation treatment for major depressive disorder: a fully remote phase 2 randomized sham-controlled trial.
Woodham RD, Selvaraj S, Lajmi N, Hobday H, et al · · 2025 · cited 68× · PMID 39433921 · DOI 10.1038/s41591-024-03305-y
Neuromodulation Strategies to Reduce Inflammation and Improve Lung Complications in COVID-19 Patients.
Czura CJ, Bikson M, Charvet L, Chen JDZ, et al · · 2022 · cited 13× · PMID 35911909 · DOI 10.3389/fneur.2022.897124
Home-based transcranial direct current stimulation RCT in major depression
Woodham RD, Selvaraj S, Lajmi N, Hobday H, et al · · 2023 · cited 3× · DOI 10.1101/2023.11.27.23299059
Acceptability of active and sham home-based transcranial direct current stimulation in major depression: mixed methods qualitative analysis in a randomised controlled trial.
Lagerberg PJ, Woodham RD, Selvaraj S, Lajmi N, et al · · 2025 · PMID 41345653 · DOI 10.1186/s12991-025-00607-4
Home-based transcranial direct current stimulation for major depressive disorder: 6-month follow-up from a randomised sham-controlled trial
Woodham RD, Selvaraj S, Lajmi N, Hobday H, et al · · 2024 · DOI 10.1101/2024.11.21.24317690

Verify or expand the search:

Other trials of Transcranial direct current stimulation

Trials testing the same drug.

NCT07444242 — Accelerated Treatment of Depressive Patients With tDCS · NA · not yet recruiting
NCT07433972 — Changes in Hemodynamic Response Following Transcranial Electrical Stimulation in Sroke Individuals · NA · not yet recruiting
NCT07257601 — TDCS-RTMS Intervention for Motor Function · NA · not yet recruiting
NCT06501820 — Neural Control of Gait & Navigation in ADRD · NA · enrolling by invitation
NCT06976697 — Home-Based tDCS Treatment Of Major Depressive Disorder · NA · recruiting

Other recruiting trials for Major Depressive Disorder

Currently open trials in the same condition.

NCT07219394 — Peer-Delivered Behavioral Activation in a CCBHC · NA · recruiting
NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor · Phase 2 · recruiting
NCT06749392 — An Individual-specific Synchrony Signature · NA · recruiting
NCT07316803 — Group Intervention for Romantic Relationships in Young Adults With Severe Mental Illness · NA · recruiting
NCT07242105 — Optimizing Brain Excitability in Depression · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05202119 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Flow Neuroscience AB
Last refreshed: 19 September 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05202119.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing